Description
This educational activity reviews current and emerging treatment strategies across the multiple myeloma care continuum. Learners will explore the role of quadruplet therapy in the frontline setting for both transplant-eligible and transplant-ineligible patients, as well as the use of CAR T-cell therapies and BCMA-targeting bispecific antibodies in relapsed/refractory disease. The activity also focuses on applying available sequencing data to develop evidence-based treatment plans for patients with relapsed/refractory multiple myeloma.
Learning Objectives
- Discuss the role of quadruplet therapy in transplant-eligible and transplant-ineligible multiple myeloma and identify appropriate use in the frontline setting
- Review chimeric antigen receptor (CAR) T-cell therapies’ use in relapsed/refractory multiple myeloma
- Summarize the role of BCMA-targeting bispecific antibodies in the management of relapsed/refractory multiple myeloma
- Determine an evidence-based treatment plan for relapsed/refractory multiple myeloma with available sequencing data
Pricing
This activity does not require payment to register.
Login and Registration
Please use the button below to access course. Reminder, you will need to sign in to Lecture Panda to save course progress.
ACCESS COURSE
To receive credit you must participate and complete all the steps found in the “Complete Credit Requirements” link provided by the registration confirmation email.
After following the link, these steps will include:
- Reviewing the course learning materials.
- Confirming information provided on registration.
- Claiming participation in applicable credits.
- Completing all listed evaluations and quizzes.
Credit requirements must be completed before the expiration date of the activity. Upon completion, credit will be transmitted electronically to the ACPE. All transmitted credit will be viewable in your CPE Monitor profile within 24 hours.
